# Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Source: https://onco.cc/trials/nct03579836/  
OnCo record `nct03579836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by BeyondBio Inc., now recruiting.

## Summary

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer is a phase 1/2 interventional study registered as NCT03579836 by BeyondBio Inc., with 75 participants planned, started 2018-05-14 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107 and Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03579836
- Phase: 1/2
- Setting: A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination with Gemcitabine in Patient with Locally Advanced or Metastatic Pancreatic Cancer
- Sponsor: BeyondBio Inc.
- Enrolled: 75

## Sources

- ClinicalTrials.gov NCT03579836: https://clinicaltrials.gov/study/NCT03579836

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct03579836.json